摘要
目的探讨血管紧张素转换酶抑制剂调控转化生长因子β1(TGF-β1)对高血压病心室重构的影响。方法将高血压病患者40例随机分为对照组20例(C组)和血管紧张素转换酶抑制剂组20例(A组);C组常规服钙离子拮抗剂+β受体阻滞剂或利尿药,A组在C组基础上加血管紧张素转换酶抑制剂,选择同期20名健康体格检查者为正常对照组(N组),N组常规服谷维素,疗程1年,治疗前后各组均抽血清测TGF-β1浓度,超声心动图测量治疗前后左室舒张末期内径(LVEDd),左室收缩末期内径(LVEDS),室间隔厚度(IVSd),左室后壁厚度(LVPWd),并计算左心室质量指数(LVMI)和左心室质量(LVM)。结果A组TGF-β1浓度、左心室质量指数和左心室质量均低于C组,TGF-β1浓度与LVMI和LVM均呈正相关。结论血管紧张素转换酶抑制剂下调TGF-β1浓度,抑制高血压病患者心室重构。
Objective To explore prospectively the pharmacological effect of angiotensin Ⅰ converting enzyme inhibitors（ACE Ⅰ ） on the hypertension ventricle remodeling via regulating transform growth factorβl. Methods Fourty patients with hypertension were randomly divided into control group（C Group, n = 20）, angiotensin Ⅰ converting enzyme inhibitors（ACE Ⅰ ）group（A Group, n = 20）. The health control group without suffering from hypertension（N Group, n = 20） basing on different remedy project. C Group cases were treated by calcium channel blocks（calcium antagonists） combined with β-acceptor antagonists or diuretics, A Group cases were treat- ed by basing on the A Group＇ remedy project combined with ACE Ⅰ. The N Group cases were treated by Oryzanol. All cases had been treated for one year. These had been examined before and after treatment the serum TGF-β1, the inner diameter of left ventricle during stretching and shrinking end period, the thickness of ventricular septal and the thickness of back wall of left ventricular septal. Left ventricle mass index and left ventricle mass had been calculated. Results The serum TGF-β1, left ventricle quality index and left ventricle quality in A Group were significantly statistical lower compared with in C Group. The serum TGF-β1 were positive correlative with left ventricle quality index and left ventricle quality. Conclusion The ACE Ⅰ inhibite hypertension ventricle remodeling basing on down-regulating the serum TGF-β1.
出处
《湘南学院学报（医学版）》
2007年第4期10-12,共3页
Journal of Xiangnan University（Medical Sciences）
